These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 18566242

  • 21. Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells.
    Torres C, Linares A, Alejandre MJ, Palomino-Morales RJ, Delgado JR, Perales S.
    Pancreas; 2016 Feb; 45(2):269-80. PubMed ID: 26495790
    [Abstract] [Full Text] [Related]

  • 22. Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line.
    Zhang QC, Jiang SJ, Zhang S, Ma XB.
    Asian Pac J Cancer Prev; 2012 Feb; 13(7):3471-6. PubMed ID: 22994780
    [Abstract] [Full Text] [Related]

  • 23. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells.
    Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH.
    Cancer; 2006 Jun 01; 106(11):2503-13. PubMed ID: 16628653
    [Abstract] [Full Text] [Related]

  • 24. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
    Zheng YT, Yang HY, Li T, Zhao B, Shao TF, Xiang XQ, Cai WM.
    Acta Pharmacol Sin; 2015 May 01; 36(5):614-26. PubMed ID: 25864651
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'-diindolylmethane-induced apoptosis in breast cancer cells.
    Rahman KW, Sarkar FH.
    Cancer Res; 2005 Jan 01; 65(1):364-71. PubMed ID: 15665315
    [Abstract] [Full Text] [Related]

  • 26. Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
    Gadgeel SM, Ali S, Philip PA, Ahmed F, Wozniak A, Sarkar FH.
    Cancer; 2007 Dec 15; 110(12):2775-84. PubMed ID: 17948911
    [Abstract] [Full Text] [Related]

  • 27. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ.
    Mol Pharmacol; 2008 Apr 15; 73(4):1290-300. PubMed ID: 18187583
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
    El-Rayes BF, Ali S, Sarkar FH, Philip PA.
    Mol Cancer Ther; 2004 Nov 15; 3(11):1421-6. PubMed ID: 15542781
    [Abstract] [Full Text] [Related]

  • 31. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.
    Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, Schwarz RE, Burrows FJ, Brekken RA.
    Clin Cancer Res; 2012 Sep 15; 18(18):5031-42. PubMed ID: 22829202
    [Abstract] [Full Text] [Related]

  • 32. Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM).
    Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM, Sarkar FH.
    Pharm Res; 2008 Sep 15; 25(9):2117-24. PubMed ID: 18427961
    [Abstract] [Full Text] [Related]

  • 33. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer.
    Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH.
    Cancer Res; 2007 Apr 01; 67(7):3310-9. PubMed ID: 17409440
    [Abstract] [Full Text] [Related]

  • 34. Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
    Kryeziu K, Jungwirth U, Hoda MA, Ferk F, Knasmüller S, Karnthaler-Benbakka C, Kowol CR, Berger W, Heffeter P.
    Mol Cancer Ther; 2013 Jun 01; 12(6):1073-84. PubMed ID: 23548265
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
    Zhang X, Zhang H, Tighiouart M, Lee JE, Shin HJ, Khuri FR, Yang CS, Chen Z', Shin DM.
    Int J Cancer; 2008 Sep 01; 123(5):1005-14. PubMed ID: 18546267
    [Abstract] [Full Text] [Related]

  • 38. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
    Dai B, Yan S, Lara-Guerra H, Kawashima H, Sakai R, Jayachandran G, Majidi M, Mehran R, Wang J, Bekele BN, Baladandayuthapani V, Yoo SY, Wang Y, Ying J, Meng F, Ji L, Roth JA.
    PLoS One; 2015 Sep 01; 10(6):e0123967. PubMed ID: 26053020
    [Abstract] [Full Text] [Related]

  • 39. Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer.
    Wang Z, Sengupta R, Banerjee S, Li Y, Zhang Y, Rahman KM, Aboukameel A, Mohammad R, Majumdar AP, Abbruzzese JL, Sarkar FH.
    Cancer Res; 2006 Aug 01; 66(15):7653-60. PubMed ID: 16885366
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.